NASDAQ:BIIB - Biogen Stock Price, Price Target & More

$259.30 -3.72 (-1.41 %)
(As of 04/24/2018 08:36 AM ET)
Previous Close$263.02
Today's Range$258.00 - $264.48
52-Week Range$244.28 - $370.57
Volume1.92 million shs
Average Volume1.66 million shs
Market Capitalization$55.65 billion
P/E Ratio11.89
Dividend YieldN/A
Beta0.86

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000

Debt

Debt-to-Equity Ratio0.47%
Current Ratio2.34%
Quick Ratio2.07%

Price-To-Earnings

Trailing P/E Ratio11.89
Forward P/E Ratio10.47
P/E Growth1.45

Sales & Book Value

Annual Sales$12.27 billion
Price / Sales4.47
Cash Flow$26.7044 per share
Price / Cash9.71
Book Value$59.56 per share
Price / Book4.35

Profitability

EPS (Most Recent Fiscal Year)$21.81
Net Income$2.54 billion
Net Margins20.69%
Return on Equity38.32%
Return on Assets20.72%

Miscellaneous

Employees7,300
Outstanding Shares211,560,000

How to Become a New Pot Stock Millionaire

Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen (NASDAQ:BIIB) released its quarterly earnings data on Thursday, January, 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $5.44 by $0.18. The biotechnology company had revenue of $3.31 billion for the quarter, compared to the consensus estimate of $3.08 billion. Biogen had a net margin of 20.69% and a return on equity of 38.32%. Biogen's revenue for the quarter was up 15.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.04 earnings per share. View Biogen's Earnings History.

When is Biogen's next earnings date?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Biogen.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided earnings per share (EPS) guidance of $24.20-25.20 for the period, compared to the Thomson Reuters consensus estimate of $24.13. The company issued revenue guidance of $12.7-13.0 billion, compared to the consensus revenue estimate of $12.68 billion.

What price target have analysts set for BIIB?

29 brokerages have issued 12-month price targets for Biogen's shares. Their predictions range from $279.00 to $433.00. On average, they anticipate Biogen's share price to reach $367.2222 in the next year. View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:
  • 1. Mizuho analysts commented, "We also note full year 2017 consensus is already above the company’s guidance on both top and bottom lines (guidance last updated in 2Q17) 1. Spinraza. We believe investors will continue to be focused on the performance of the Spinraza launch and information from management on uptake trends. At the recent JPM conference, BIIB commented that for Spinraza they see a benefit from the new launch period in large territories and then a moderate rate of growth, noting that they see reasonable growth in the US in the coming quarters and that a lot of the growth will come outside the US as new countries receive approvals. This was similar to commentary from management in the 3Q17 call. Consensus has 4Q over 3Q growth of 11% and 51% in the US and Ex-US for Spinraza." (1/18/2018)
  • 2. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
  • 3. Citigroup analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
  • 4. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
  • 5. Cowen Inc analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:
  • Mr. Michel Vounatsos, CEO & Director (Age 56)
  • Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)
  • Mr. Jeffrey D. Capello, Exec. VP of Fin. & CFO (Age 53)
  • Mr. Gregory F. Covino, VP of Fin. & Chief Accounting Officer (Age 52)
  • Mr. Mark J. Hernon, Sr. VP & Chief Information Officer (Age 54)

Has Biogen been receiving favorable news coverage?

Press coverage about BIIB stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biogen earned a news impact score of 0.13 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 49.30 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include PRIMECAP MANAGEMENT COMPANY (7.16%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $259.30.

How big of a company is Biogen?

Biogen has a market capitalization of $55.65 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.


MarketBeat Community Rating for Biogen (BIIB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,267 (Vote Outperform)
Underperform Votes:  739 (Vote Underperform)
Total Votes:  2,006
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biogen (NASDAQ:BIIB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
29 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $367.2222, suggesting that the stock has a possible upside of 41.62%. The high price target for BIIB is $433.00 and the low price target for BIIB is $279.00. There are currently 9 hold ratings and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.722.762.67
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
20 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $367.2222$370.9259$355.25$341.08
Price Target Upside: 41.62% upside32.52% upside2.45% upside8.03% upside

Biogen (NASDAQ:BIIB) Consensus Price Target History

Price Target History for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Credit Suisse GroupSet Price TargetBuy$384.00MediumView Rating Details
4/11/2018MizuhoSet Price TargetBuy$433.00LowView Rating Details
4/10/2018Sanford C. BernsteinSet Price TargetBuy$318.00MediumView Rating Details
4/9/2018Canaccord GenuitySet Price TargetHold$350.00MediumView Rating Details
4/5/2018BarclaysDowngradeOverweight -> Equal Weight$395.00 -> $295.00HighView Rating Details
3/2/2018GuggenheimSet Price TargetBuy$400.00LowView Rating Details
3/2/2018BMO Capital MarketsLower Price TargetOutperform -> Outperform$403.00 -> $393.00LowView Rating Details
2/16/2018ArgusDowngradeBuy -> HoldMediumView Rating Details
2/15/2018William BlairReiterated RatingBuyLowView Rating Details
2/8/2018JPMorgan ChaseReiterated RatingBuyHighView Rating Details
1/31/2018UBSUpgradeNeutral -> Buy$352.59 -> $410.00LowView Rating Details
1/26/2018OppenheimerBoost Price TargetOutperform -> Buy$380.00 -> $400.00LowView Rating Details
1/26/2018Deutsche BankReiterated RatingBuy$373.00LowView Rating Details
1/26/2018Jefferies GroupReiterated RatingHoldMediumView Rating Details
1/26/2018Royal Bank of CanadaBoost Price TargetSector Perform$347.00HighView Rating Details
1/26/2018SunTrust BanksBoost Price TargetBuy$392.00HighView Rating Details
1/26/2018HC WainwrightReiterated RatingBuy -> Buy$340.00 -> $363.00HighView Rating Details
1/26/2018CowenReiterated RatingBuy$408.00HighView Rating Details
1/25/2018Robert W. BairdReiterated RatingNeutral -> HoldHighView Rating Details
1/25/2018Goldman SachsSet Price TargetBuy$390.00MediumView Rating Details
1/16/2018CitigroupReiterated RatingOutperform$350.00 -> $380.00MediumView Rating Details
1/2/2018Piper JaffrayReiterated RatingBuyHighView Rating Details
12/30/2017NomuraBoost Price TargetBuy$355.00 -> $420.00N/AView Rating Details
10/24/2017Cantor FitzgeraldReiterated RatingHold$279.00N/AView Rating Details
10/18/2017Bank of AmericaBoost Price TargetBuy$358.00 -> $365.00N/AView Rating Details
10/17/2017Morgan StanleyReiterated RatingBuyN/AView Rating Details
10/17/2017Stifel NicolausUpgradeHold -> Buy$300.00 -> $415.00N/AView Rating Details
9/21/2017Raymond JamesDowngradeStrong-Buy -> Market Perform$244.28 -> $319.00LowView Rating Details
7/26/2017Leerink SwannReiterated RatingMarket Perform$304.00 -> $338.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells FargoReiterated RatingBuyN/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Biogen (NASDAQ:BIIB) Earnings History and Estimates Chart

Earnings by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) Earnings Estimates

2018 EPS Consensus Estimate: $24.80
2019 EPS Consensus Estimate: $26.37
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20186$5.54$6.04$5.93
Q2 20186$6.24$6.43$6.34
Q3 20186$6.19$6.45$6.32
Q4 20186$5.99$6.48$6.22
Q1 20193$6.18$6.30$6.25
Q2 20193$6.53$6.76$6.67
Q3 20192$6.70$6.92$6.81
Q4 20192$6.35$6.93$6.64

Biogen (NASDAQ BIIB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/24/2018Q1 2018$5.89N/AView Earnings Details
1/25/2018Q4 2017$5.44$5.26$3.0841 billion$3.3070 billionViewListenView Earnings Details
10/24/2017Q3 2017$5.70$6.31$3.0467 billion$3.0780 billionViewN/AView Earnings Details
7/25/2017Q2 2017$4.36$5.04$2.8133 billion$3.0780 billionViewN/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.7287 billion$2.8110 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
10/26/2010Q3 2010$1.20$1.33ViewN/AView Earnings Details
7/20/2010Q2 2010$1.08$1.28ViewN/AView Earnings Details
4/20/2010Q1 2010$1.12$1.05ViewN/AView Earnings Details
2/9/2010Q4 2009$1.05$1.17ViewN/AView Earnings Details
10/20/2009Q3 2009$1.02$1.09ViewN/AView Earnings Details
7/16/2009Q2 2009$0.89$0.73ViewN/AView Earnings Details
4/16/2009Q1 2009$1.00$1.05ViewN/AView Earnings Details
2/6/2009Q4 2008$0.88$0.91ViewN/AView Earnings Details
10/21/2008Q3 2008$0.89$0.95ViewN/AView Earnings Details
7/22/2008Q2 2008$0.83$0.91ViewN/AView Earnings Details
4/23/2008Q1 2008$0.78$0.82ViewN/AView Earnings Details
2/6/2008Q4 2007$0.79$0.89ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Biogen (NASDAQ:BIIB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 88.94%
Insider Trading History for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ BIIB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/27/2018Alfred SandrockEVPSell259$290.83$75,324.976,553View SEC Filing  
2/20/2018Alfred SandrockEVPSell743$292.00$216,956.006,553View SEC Filing  
2/15/2018Alfred SandrockEVPSell1,294$298.85$386,711.907,296View SEC Filing  
1/9/2018Robert W PangiaDirectorSell5,832$329.65$1,922,518.8023,539View SEC Filing  
12/29/2017Michel VounatsosCEOBuy780$320.55$250,029.00View SEC Filing  
12/29/2017Michel VounatsosCEOBuy780$320.55$250,029.004,879View SEC Filing  
11/29/2017Alexander J DennerDirectorBuy30,000$317.36$9,520,800.0010,029View SEC Filing  
7/25/2017Susan H AlexanderEVPSell4,974$290.01$1,442,509.7422,258View SEC Filing  
7/19/2017Susan H AlexanderEVPSell7,758$285.00$2,211,030.0027,232View SEC Filing  
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.046,330View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.0010,813View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.487,060View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.0520,705View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.5022,078View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.287,579View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.007,172View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.0019,663View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.0054,779View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.002,402View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.0054,936View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.7056,265View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.0059,633View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.3859,790View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.001,848View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.0060,277View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.2160,434View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.1960,921View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.608,127View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.707,990View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.527,990View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.9259,848View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.087,740View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.007,740View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.007,890View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.155,749View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.8824,019View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.006,970View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.6626,142View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.0014,003View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.006,435View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.0014,468View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.457,976View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.438,191View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.243,511View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.1854,389View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.1621,407View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.809,412View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.3513,667View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.3652,961View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.8010,440View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.003,325View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.0018,509View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.5014,003View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.003,325View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.008,710View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.007,087View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.984,885View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.107,087View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.008,710View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.6043,522View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.804,571View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biogen (NASDAQ BIIB) News Headlines

Source:
DateHeadline
Your Daily Pharma Scoop: Roches Ocrevus, Biogen Data, Biohaven UpdateYour Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
seekingalpha.com - April 24 at 8:17 AM
Biogen Q1 18 Earnings Conference Call At 8:30 AM ETBiogen Q1 18 Earnings Conference Call At 8:30 AM ET
www.nasdaq.com - April 24 at 8:17 AM
BRIEF-Biogen Reports Quarterly Revenues Of $3.1 BillionBRIEF-Biogen Reports Quarterly Revenues Of $3.1 Billion
www.reuters.com - April 24 at 8:17 AM
Biogen reports Q1 profit beat, sales missBiogen reports Q1 profit beat, sales miss
www.marketwatch.com - April 24 at 8:17 AM
Biogen quarterly profit jumps on higher Spinraza salesBiogen quarterly profit jumps on higher Spinraza sales
finance.yahoo.com - April 24 at 8:17 AM
Biogen revenue climbs; Spinraza, Tecfidera sales missBiogen revenue climbs; Spinraza, Tecfidera sales miss
finance.yahoo.com - April 24 at 8:17 AM
Biogen stock drops 2% after Q1 sales missBiogen stock drops 2% after Q1 sales miss
finance.yahoo.com - April 24 at 8:17 AM
Biogens SMA med Spinraza shows longer-term treatment effect in extension studyBiogen's SMA med Spinraza shows longer-term treatment effect in extension study
seekingalpha.com - April 23 at 5:15 PM
Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS CollaborationNomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration
www.streetinsider.com - April 23 at 5:15 PM
Your Daily Pharma Scoop: Abeonas ABO-202, Revance Update, Ionis/Biogens New CollaborationYour Daily Pharma Scoop: Abeona's ABO-202, Revance Update, Ionis/Biogen's New Collaboration
seekingalpha.com - April 23 at 8:13 AM
Biogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN MeetingsBiogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN Meetings
www.streetinsider.com - April 23 at 8:13 AM
Biotech Analysis Central Pharma News: Biogens Deal, Eli Lilly Partner Incyte Refile Baricitinib, Argos Loses OutBiotech Analysis Central Pharma News: Biogen's Deal, Eli Lilly Partner Incyte Refile Baricitinib, Argos Loses Out
seekingalpha.com - April 23 at 8:13 AM
Why Is Biogen Inc. Giving Ionis Another $1 Billion?Why Is Biogen Inc. Giving Ionis Another $1 Billion?
finance.yahoo.com - April 23 at 8:13 AM
Brainstorm Health: Marijuana Health Effects, Biogen Ionis Deal, Googles AI ReachBrainstorm Health: Marijuana Health Effects, Biogen Ionis Deal, Google's AI Reach
fortune.com - April 21 at 8:17 AM
Biogen (BIIB) Lifted to "Neutral" at UBSBiogen (BIIB) Lifted to "Neutral" at UBS
www.americanbankingnews.com - April 20 at 9:12 PM
Biogen and Ionis form partnership in $1B deal to fight brain disordersBiogen and Ionis form partnership in $1B deal to fight brain disorders
www.cnbc.com - April 20 at 5:23 PM
BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of ...BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of ...
www.reuters.com - April 20 at 5:23 PM
Biogen (BIIB) Earns "Outperform" Rating from William BlairBiogen (BIIB) Earns "Outperform" Rating from William Blair
www.americanbankingnews.com - April 20 at 4:17 PM
Earnings Outlook: A tale of two deals—ahead of earnings, Biogen move perplexes Earnings Outlook: A tale of two deals—ahead of earnings, Biogen move perplexes
www.marketwatch.com - April 20 at 12:17 PM
Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases ...Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases ...
www.streetinsider.com - April 20 at 8:21 AM
Ionis Pharmaceuticals stock soars as Biogen collaboration deal includes $1 billion paymentIonis Pharmaceuticals' stock soars as Biogen collaboration deal includes $1 billion payment
finance.yahoo.com - April 20 at 8:21 AM
Biogen to pay $1 billion to Ionis in new partnershipBiogen to pay $1 billion to Ionis in new partnership
finance.yahoo.com - April 20 at 8:21 AM
Biogen To Pay Ionis $1 Billion To Develop Brain DrugsBiogen To Pay Ionis $1 Billion To Develop Brain Drugs
finance.yahoo.com - April 20 at 8:21 AM
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological DiseasesBiogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
finance.yahoo.com - April 20 at 8:21 AM
Biogen boosts investment in neurology with $1 billion Ionis dealBiogen boosts investment in neurology with $1 billion Ionis deal
finance.yahoo.com - April 20 at 8:21 AM
Ionis up 8% premarket on new $1B 10-year collaboration with Biogen in neurological diseasesIonis up 8% premarket on new $1B 10-year collaboration with Biogen in neurological diseases
seekingalpha.com - April 20 at 7:15 AM
Biogen (BIIB) Given Hold Rating at Jefferies GroupBiogen (BIIB) Given Hold Rating at Jefferies Group
www.americanbankingnews.com - April 19 at 3:35 PM
Q2 2018 Earnings Forecast for Biogen Issued By Leerink Swann (BIIB)Q2 2018 Earnings Forecast for Biogen Issued By Leerink Swann (BIIB)
www.americanbankingnews.com - April 19 at 6:44 AM
Biogen (BIIB) Upgraded at VetrBiogen (BIIB) Upgraded at Vetr
www.americanbankingnews.com - April 19 at 12:28 AM
Biogen (BIIB) Missed Out on AveXis (AVXS) But Well-Positioned for Substantial Acquisition - RBCBiogen (BIIB) Missed Out on AveXis (AVXS) But Well-Positioned for Substantial Acquisition - RBC
www.streetinsider.com - April 18 at 5:47 PM
Biogen (BIIB) Given a $384.00 Price Target at Credit Suisse GroupBiogen (BIIB) Given a $384.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - April 18 at 8:40 AM
Q1 2018 Earnings Estimate for Biogen (BIIB) Issued By Leerink SwannQ1 2018 Earnings Estimate for Biogen (BIIB) Issued By Leerink Swann
www.americanbankingnews.com - April 18 at 7:58 AM
Biogen (BIIB) Given Hold Rating at BMO Capital MarketsBiogen (BIIB) Given Hold Rating at BMO Capital Markets
www.americanbankingnews.com - April 17 at 8:07 PM
Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and ...Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and ...
www.businesswire.com - April 17 at 8:27 AM
Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative DiseasesBiogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases
finance.yahoo.com - April 17 at 8:26 AM
Biogen (BIIB) Scheduled to Post Earnings on TuesdayBiogen (BIIB) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - April 17 at 1:41 AM
How Did Biogen Miss AveXis?How Did Biogen Miss AveXis?
finance.yahoo.com - April 16 at 5:27 PM
Factors of Influence in 2018, Key Indicators and Opportunity within McDonalds, Biogen, Freeport-McMoRan ...Factors of Influence in 2018, Key Indicators and Opportunity within McDonald's, Biogen, Freeport-McMoRan ...
globenewswire.com - April 16 at 8:13 AM
Factors of Influence in 2018, Key Indicators and Opportunity within McDonalds, Biogen, Freeport-McMoRan, Community Health, Enphase Energy, and Exxon Mobil — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within McDonald's, Biogen, Freeport-McMoRan, Community Health, Enphase Energy, and Exxon Mobil — New Research Emphasizes Economic Growth
finance.yahoo.com - April 16 at 8:13 AM
Biogen to Post Q1 2018 Earnings of $6.00 Per Share, Piper Jaffray Forecasts (BIIB)Biogen to Post Q1 2018 Earnings of $6.00 Per Share, Piper Jaffray Forecasts (BIIB)
www.americanbankingnews.com - April 16 at 1:44 AM
Biogen (BIIB) Upgraded by Goldman Sachs to BuyBiogen (BIIB) Upgraded by Goldman Sachs to Buy
www.americanbankingnews.com - April 15 at 9:29 PM
Biogen (BIIB) Downgraded to "Hold" at VetrBiogen (BIIB) Downgraded to "Hold" at Vetr
www.americanbankingnews.com - April 15 at 8:22 PM
Biogens (BIIB) Buy Rating Reiterated at CowenBiogen's (BIIB) Buy Rating Reiterated at Cowen
www.americanbankingnews.com - April 15 at 7:48 PM
Biogen (BIIB) Receives Consensus Rating of "Buy" from AnalystsBiogen (BIIB) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 1:40 PM
Why One Drug Flop Tanked Incytes StockWhy One Drug Flop Tanked Incyte's Stock
www.fool.com - April 13 at 8:17 AM
Biogen’s Key Drug for the Treatment of Spinal Muscular AtrophyBiogen’s Key Drug for the Treatment of Spinal Muscular Atrophy
finance.yahoo.com - April 12 at 5:40 PM
Biogen up 1% on potential sale of part of Bioepis stake to Samsung GroupBiogen up 1% on potential sale of part of Bioepis stake to Samsung Group
seekingalpha.com - April 12 at 8:32 AM
The Zacks Analyst Blog Highlights: NextEra, Danaher, Biogen, Facebook and AppleThe Zacks Analyst Blog Highlights: NextEra, Danaher, Biogen, Facebook and Apple
finance.yahoo.com - April 12 at 8:32 AM
What Analysts Recommend for Incyte in April 2018What Analysts Recommend for Incyte in April 2018
finance.yahoo.com - April 11 at 5:34 PM
Mizuho: Samsung Bioepis Renegotiation A Positive For BiogenMizuho: Samsung Bioepis Renegotiation 'A Positive' For Biogen
finance.yahoo.com - April 11 at 5:34 PM

SEC Filings

Biogen (NASDAQ:BIIB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biogen (NASDAQ BIIB) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.